Osaka, Japan

Takayuki Inukai

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Takayuki Inukai: Innovator in Quinoline Derivatives

Introduction

Takayuki Inukai is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly through his work on quinoline derivatives. With a total of 8 patents to his name, Inukai's innovations are paving the way for new therapeutic agents.

Latest Patents

Inukai's latest patents focus on a quinoline derivative that exhibits strong Axl inhibitory activity. This compound is characterized by a unique bicyclic structure, where a saturated carbon ring is fused to a pyridone ring. The therapeutic potential of this compound extends to Axl-related diseases, including various types of cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma. Additionally, it shows promise in treating kidney diseases, immune system disorders, and circulatory system diseases.

Career Highlights

Throughout his career, Takayuki Inukai has worked with notable companies, including Ono Pharmaceutical Co., Ltd. and Ono Pharmaceuticals Co., Ltd. His work in these organizations has contributed to advancements in pharmaceutical research and development.

Collaborations

Inukai has collaborated with esteemed colleagues such as Jun Takeuchi and Tomoko Yasuhiro. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Takayuki Inukai's contributions to the field of medicinal chemistry, particularly through his work on quinoline derivatives, highlight his role as an influential inventor. His ongoing research and patents continue to hold promise for the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…